Review



product mab35  (Developmental Studies Hybridoma Bank)


Bioz Verified Symbol Developmental Studies Hybridoma Bank is a verified supplier
Bioz Manufacturer Symbol Developmental Studies Hybridoma Bank manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Developmental Studies Hybridoma Bank product mab35
    A) After baseline measurements on day 0, subcutaneous treatment injections were administered on day 1 and 8. Intermediate testing and blood collection were performed on day 4, 7 and 11 (not shown). On day 15, indicated with a red arrow, PTMG was induced using <t>mAb35,</t> while non-MG animals received a saline injection of the same volume. B-C) Plasma C3 expression was reduced by the sc administration of C3-siRNA at various dose levels in B) non-MG animals and C) PTMG animals. For animals receiving 2 x 30 mg/kg treatment, doses were administered on days 1 and 8. For animals receiving 1 x 10 or 1 x 30 mg/kg doses, administration occurred on day 8, as indicated by the black arrows on the graphs. Saline-treated animals showed no significant change in C3 levels over time. Group averages are shown. D) Plasma C3 level changes in individual treatment groups on day 17, normalized to baseline levels on day 0. Individual plasma C3 levels per animal are shown. Statistical analysis was performed with Two-Way ANOVA (B-D), followed by One-Way ANOVA and post-hoc Bonferroni’s multiple comparison test (D); α=0.05; ****p<0.0001. A) Created in BioRender. Schöttler, A. (2025) https://BioRender.com/b4xxodd .
    Product Mab35, supplied by Developmental Studies Hybridoma Bank, used in various techniques. Bioz Stars score: 94/100, based on 29 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/product+mab35/anti-Acetylcholine+receptor+nicotinic+alpha+1+subunit/bio_rxiv__2025__08__31__673367-64-30-25
    Average 94 stars, based on 29 article reviews
    product mab35 - by Bioz Stars, 2026-10
    94/100 stars

    Images

    1) Product Images from "Complement inhibition by C3-siRNA treatment prevents AChR loss and reduces complement activation in the rat Passive Transfer Myasthenia Gravis (PTMG)"

    Article Title: Complement inhibition by C3-siRNA treatment prevents AChR loss and reduces complement activation in the rat Passive Transfer Myasthenia Gravis (PTMG)

    Journal: bioRxiv

    doi: 10.1101/2025.08.31.673367

    A) After baseline measurements on day 0, subcutaneous treatment injections were administered on day 1 and 8. Intermediate testing and blood collection were performed on day 4, 7 and 11 (not shown). On day 15, indicated with a red arrow, PTMG was induced using mAb35, while non-MG animals received a saline injection of the same volume. B-C) Plasma C3 expression was reduced by the sc administration of C3-siRNA at various dose levels in B) non-MG animals and C) PTMG animals. For animals receiving 2 x 30 mg/kg treatment, doses were administered on days 1 and 8. For animals receiving 1 x 10 or 1 x 30 mg/kg doses, administration occurred on day 8, as indicated by the black arrows on the graphs. Saline-treated animals showed no significant change in C3 levels over time. Group averages are shown. D) Plasma C3 level changes in individual treatment groups on day 17, normalized to baseline levels on day 0. Individual plasma C3 levels per animal are shown. Statistical analysis was performed with Two-Way ANOVA (B-D), followed by One-Way ANOVA and post-hoc Bonferroni’s multiple comparison test (D); α=0.05; ****p<0.0001. A) Created in BioRender. Schöttler, A. (2025) https://BioRender.com/b4xxodd .
    Figure Legend Snippet: A) After baseline measurements on day 0, subcutaneous treatment injections were administered on day 1 and 8. Intermediate testing and blood collection were performed on day 4, 7 and 11 (not shown). On day 15, indicated with a red arrow, PTMG was induced using mAb35, while non-MG animals received a saline injection of the same volume. B-C) Plasma C3 expression was reduced by the sc administration of C3-siRNA at various dose levels in B) non-MG animals and C) PTMG animals. For animals receiving 2 x 30 mg/kg treatment, doses were administered on days 1 and 8. For animals receiving 1 x 10 or 1 x 30 mg/kg doses, administration occurred on day 8, as indicated by the black arrows on the graphs. Saline-treated animals showed no significant change in C3 levels over time. Group averages are shown. D) Plasma C3 level changes in individual treatment groups on day 17, normalized to baseline levels on day 0. Individual plasma C3 levels per animal are shown. Statistical analysis was performed with Two-Way ANOVA (B-D), followed by One-Way ANOVA and post-hoc Bonferroni’s multiple comparison test (D); α=0.05; ****p<0.0001. A) Created in BioRender. Schöttler, A. (2025) https://BioRender.com/b4xxodd .

    Techniques Used: Saline, Injection, Clinical Proteomics, Expressing, Comparison

    Related Articles

    Injection:

    Article Title: Complement inhibition by C3-siRNA treatment prevents AChR loss and reduces complement activation in the rat Passive Transfer Myasthenia Gravis (PTMG)
    Article Snippet: .. PTMG was induced at 11-weeks of age by sc injection of 40 pmol/100 g body weight of mAb35 [deposited to the DSHB by Lindstrom, J. (Developmental Studies Hybridoma Bank (DSHB) product mAb35) on day 15, after C3-siRNA treatment. .. PTMG was induced at 11-weeks of age by sc injection of 40 pmol/100 g body weight of mAb35 [deposited to the DSHB by Lindstrom, J. (Developmental Studies Hybridoma Bank (DSHB) product mAb35) on day 15, after C3-siRNA treatment.



    Similar Products

    monoclonal antibody 35 production  (ATCC)
    94
    ATCC monoclonal antibody 35 production
    Monoclonal Antibody 35 Production, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/product+mab35/mAb35/pm41006369-179-0-15
    Average 94 stars, based on 1 article reviews
    monoclonal antibody 35 production - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    product mab35  (Developmental Studies Hybridoma Bank)
    94
    Developmental Studies Hybridoma Bank product mab35
    A) After baseline measurements on day 0, subcutaneous treatment injections were administered on day 1 and 8. Intermediate testing and blood collection were performed on day 4, 7 and 11 (not shown). On day 15, indicated with a red arrow, PTMG was induced using <t>mAb35,</t> while non-MG animals received a saline injection of the same volume. B-C) Plasma C3 expression was reduced by the sc administration of C3-siRNA at various dose levels in B) non-MG animals and C) PTMG animals. For animals receiving 2 x 30 mg/kg treatment, doses were administered on days 1 and 8. For animals receiving 1 x 10 or 1 x 30 mg/kg doses, administration occurred on day 8, as indicated by the black arrows on the graphs. Saline-treated animals showed no significant change in C3 levels over time. Group averages are shown. D) Plasma C3 level changes in individual treatment groups on day 17, normalized to baseline levels on day 0. Individual plasma C3 levels per animal are shown. Statistical analysis was performed with Two-Way ANOVA (B-D), followed by One-Way ANOVA and post-hoc Bonferroni’s multiple comparison test (D); α=0.05; ****p<0.0001. A) Created in BioRender. Schöttler, A. (2025) https://BioRender.com/b4xxodd .
    Product Mab35, supplied by Developmental Studies Hybridoma Bank, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/product+mab35/anti-Acetylcholine+receptor+nicotinic+alpha+1+subunit/bio_rxiv__2025__08__31__673367-64-30-25
    Average 94 stars, based on 1 article reviews
    product mab35 - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    A) After baseline measurements on day 0, subcutaneous treatment injections were administered on day 1 and 8. Intermediate testing and blood collection were performed on day 4, 7 and 11 (not shown). On day 15, indicated with a red arrow, PTMG was induced using mAb35, while non-MG animals received a saline injection of the same volume. B-C) Plasma C3 expression was reduced by the sc administration of C3-siRNA at various dose levels in B) non-MG animals and C) PTMG animals. For animals receiving 2 x 30 mg/kg treatment, doses were administered on days 1 and 8. For animals receiving 1 x 10 or 1 x 30 mg/kg doses, administration occurred on day 8, as indicated by the black arrows on the graphs. Saline-treated animals showed no significant change in C3 levels over time. Group averages are shown. D) Plasma C3 level changes in individual treatment groups on day 17, normalized to baseline levels on day 0. Individual plasma C3 levels per animal are shown. Statistical analysis was performed with Two-Way ANOVA (B-D), followed by One-Way ANOVA and post-hoc Bonferroni’s multiple comparison test (D); α=0.05; ****p<0.0001. A) Created in BioRender. Schöttler, A. (2025) https://BioRender.com/b4xxodd .

    Journal: bioRxiv

    Article Title: Complement inhibition by C3-siRNA treatment prevents AChR loss and reduces complement activation in the rat Passive Transfer Myasthenia Gravis (PTMG)

    doi: 10.1101/2025.08.31.673367

    Figure Lengend Snippet: A) After baseline measurements on day 0, subcutaneous treatment injections were administered on day 1 and 8. Intermediate testing and blood collection were performed on day 4, 7 and 11 (not shown). On day 15, indicated with a red arrow, PTMG was induced using mAb35, while non-MG animals received a saline injection of the same volume. B-C) Plasma C3 expression was reduced by the sc administration of C3-siRNA at various dose levels in B) non-MG animals and C) PTMG animals. For animals receiving 2 x 30 mg/kg treatment, doses were administered on days 1 and 8. For animals receiving 1 x 10 or 1 x 30 mg/kg doses, administration occurred on day 8, as indicated by the black arrows on the graphs. Saline-treated animals showed no significant change in C3 levels over time. Group averages are shown. D) Plasma C3 level changes in individual treatment groups on day 17, normalized to baseline levels on day 0. Individual plasma C3 levels per animal are shown. Statistical analysis was performed with Two-Way ANOVA (B-D), followed by One-Way ANOVA and post-hoc Bonferroni’s multiple comparison test (D); α=0.05; ****p<0.0001. A) Created in BioRender. Schöttler, A. (2025) https://BioRender.com/b4xxodd .

    Article Snippet: PTMG was induced at 11-weeks of age by sc injection of 40 pmol/100 g body weight of mAb35 [deposited to the DSHB by Lindstrom, J. (Developmental Studies Hybridoma Bank (DSHB) product mAb35) on day 15, after C3-siRNA treatment.

    Techniques: Saline, Injection, Clinical Proteomics, Expressing, Comparison